Opinion

Video

Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.

  1. Based on your experience, how have topical treatments evolved beyond the use of topical steroids and topical calcineurin inhibitors?
  2. When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo